

BIOGEN IDEC INC.  
Form 4  
July 27, 2007

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Kowolenko Michael

(Last) (First) (Middle)

14 CAMBRIDGE CENTER

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
BIOGEN IDEC INC. [BIIB]

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/25/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

SVP, Pharm Ops & Technology

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	Price		
Common Stock	07/25/2007		M <sup>(1)</sup>		3,450	\$ 42.12	21,573.856 (2)	D
Common Stock	07/25/2007		M <sup>(1)</sup>		4,356	\$ 37.45	25,929.856	D
Common Stock	07/25/2007		M <sup>(1)</sup>		8,438	\$ 43.5	34,367.856	D
Common Stock	07/25/2007		M <sup>(1)</sup>		4,263	\$ 44.24	38,630.856	D
Common Stock	07/25/2007		S <sup>(1)</sup>		20,507	\$ 58	18,123.856	D

Edgar Filing: BIOGEN IDEC INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to buy)	\$ 42.12	07/25/2007		M <sup>(1)</sup>	3,450	<sup>(3)</sup> 04/01/2012	Common Stock	3,450
Stock Option (Right to buy)	\$ 37.45	07/25/2007		M <sup>(1)</sup>	4,356	<sup>(5)</sup> 12/06/2012	Common Stock	4,356
Stock Option (Right to buy)	\$ 43.5	07/25/2007		M <sup>(1)</sup>	8,438	<sup>(6)</sup> 02/06/2014	Common Stock	8,438
Stock Option (Right to buy)	\$ 44.24	07/25/2007		M <sup>(1)</sup>	4,263	<sup>(7)</sup> 02/06/2016	Common Stock	4,263

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

Kowolenko Michael  
14 CAMBRIDGE CENTER  
CAMBRIDGE, MA 02142

SVP, Pharm Ops & Technology

## Signatures

Robert A. Licht, Attorney in Fact for Michael  
Kowolenko

07/27/2007

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) Includes 117,926 shares acquired on March 30, 2007 and 39,499 shares acquired on June 29, 2007 under the Biogen Idec Inc. Employee Stock Purchase Plan.
- (3) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 04/01/02.
- (4) Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).
- (5) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/06/02.
- (6) The stock options become exercisable in four (4) equal annual installments on 12/31/04, 12/31/05, 12/31/06 and 12/31/07.
- (7) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/06/06.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.